Cargando…
SAT-621 An Atypical Case of Nivolumab-Induced Thyroiditis with Persistently Elevated Thyroid-Stimulating Immunoglobulin
BACKGROUND: The anti-PD1 monoclonal antibody nivolumab, approved for treatment of several cancers, is associated with ~ 3% rate of hyperthyroidism. Most cases are due to destructive thyroiditis. Stimulating antibodies against the TSH receptor (TSH-R) have not been reported in nivolumab-associated th...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552309/ http://dx.doi.org/10.1210/js.2019-SAT-621 |